Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Accounts Payables (2023 - 2025)

Xenetic Biosciences' Accounts Payables history spans 6 years, with the latest figure at $709916.0 for Q4 2025.

  • For Q4 2025, Accounts Payables rose 150.31% year-over-year to $709916.0; the TTM value through Dec 2025 reached $709916.0, up 150.31%, while the annual FY2025 figure was $709916.0, 150.31% up from the prior year.
  • Accounts Payables reached $709916.0 in Q4 2025 per XBIO's latest filing, up from $578250.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $709916.0 in Q4 2025 to a low of $240293.0 in Q1 2025.
  • Average Accounts Payables over 3 years is $427370.9, with a median of $397693.0 recorded in 2023.
  • Peak YoY movement for Accounts Payables: plummeted 56.37% in 2024, then soared 150.31% in 2025.
  • A 3-year view of Accounts Payables shows it stood at $240832.0 in 2023, then rose by 17.76% to $283615.0 in 2024, then skyrocketed by 150.31% to $709916.0 in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Accounts Payables are $709916.0 (Q4 2025), $578250.0 (Q3 2025), and $346828.0 (Q2 2025).